[{"id":"85055237-577b-4c03-b564-e7f118cc30e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06637501","created_at":"2025-02-25T14:11:41.845Z","updated_at":"2025-02-25T14:11:41.845Z","phase":"Phase 2","brief_title":"A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT06637501","lead_sponsor":"BeiGene","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)"],"overall_status":"Recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 11/14/2024","start_date":" 11/14/2024","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 06/01/2030","study_completion_date":" 06/01/2030","last_update_posted":"2025-02-19"},{"id":"d47210cd-de05-419e-be0b-3ae8833c707d","acronym":"BGB-11417-108","url":"https://clinicaltrials.gov/study/NCT06697184","created_at":"2025-02-25T14:05:04.300Z","updated_at":"2025-02-25T14:05:04.300Z","phase":"Phase 1/2","brief_title":"A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.","source_id_and_acronym":"NCT06697184 - BGB-11417-108","lead_sponsor":"BeiGene","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 01/23/2025","start_date":" 01/23/2025","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-19"},{"id":"99c5ce8b-5c38-453f-ad28-f12ae4fd578b","acronym":"BGB-11417-203","url":"https://clinicaltrials.gov/study/NCT05952037","created_at":"2023-07-20T14:08:47.056Z","updated_at":"2025-02-25T17:39:02.716Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Sonrotoclax in Participants With Waldenström's Macroglobulinemia","source_id_and_acronym":"NCT05952037 - BGB-11417-203","lead_sponsor":"BeiGene","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)"],"overall_status":"Recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 09/28/2023","start_date":" 09/28/2023","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2025-01-29"},{"id":"e42b7ff5-d96a-4fd9-92ca-207ab8db3cdd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05471843","created_at":"2022-07-25T21:55:26.801Z","updated_at":"2024-07-02T16:34:37.549Z","phase":"Phase 1/2","brief_title":"Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT05471843","lead_sponsor":"BeiGene","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sonrotoclax (BGB-11417)"],"overall_status":"Recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 09/05/2022","start_date":" 09/05/2022","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-06-06"},{"id":"04840d0e-2bde-4d03-ace9-5a9cdb7de1f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06367374","created_at":"2024-04-16T17:44:20.740Z","updated_at":"2024-07-02T16:35:09.492Z","phase":"Phase 2","brief_title":"MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL","source_id_and_acronym":"NCT06367374","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 05/30/2024","start_date":" 05/30/2024","primary_txt":" Primary completion: 02/28/2030","primary_completion_date":" 02/28/2030","study_txt":" Completion: 07/30/2030","study_completion_date":" 07/30/2030","last_update_posted":"2024-04-16"}]